Bristol-Myers Squibb taps Taris ’ drug-release tech for bladder cancer trial

Bristol-Myers Squibb (NYSE:BMY) and Taris Biomedical have inked a deal to combine Taris’ investigational GemRIS drug-releasing tech with the pharma company’s PD-1 immune checkpoint inhibitor, Opdivo, in a Phase Ib muscle invasive bladder cancer trial. As part of the collaboration, Bristol-Myers has also made an equity investment in Lexington, Mass.-based Taris. Get the full story at our sister site, Drug Delivery Business News. The post Bristol-Myers Squibb taps Taris’ drug-release tech for bladder cancer trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Clinical Trials Drug-Device Combinations Oncology Pharma Pharmaceuticals Wall Street Beat Bristol-Myers Squibb Co. Taris Biomedical Source Type: news